tbuckley/cabot-search huggingface dataset:
Timing of Operations and Outcomes for Patients With Hip Fracture—It’s Probably Not Worth the Wait
Authors: Mark S. Vrahas, Harry C. Sax
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neoadjuvant modified FOLFOXIRI followed by laparoscopic surgery for locally advanced rectal cancer: A retrospective study
Authors: H. Kodama, T. Terazawa, K. Higuchi, M. Goto, T. Kii, S. Kuwakado, H. Nishitani, F. Shimamoto, K. Asaishi, T. Yamaguchi, M. Aoki
Journal: Annals of Oncology (2017)
The Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Quality of Life and Productivity: Results from the International MPN Landmark Survey
Authors: Claire N. Harrison, Steffen Koschmieder, Lynda Foltz, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller, Ruben A. Mesa
Journal: Blood (2016)
Four Conversations: A randomized control trial of an online, shared decision making curriculum among the metastatic breast cancer community.
Authors: Sophia Kustas Smith, Kelly E. Westbrook, Kristin MacDermott, Matthew Roger LeBlanc, Sathya Amarasekara, Wei Pan
Journal: Journal of Clinical Oncology (2017)

47 Background: Evidence shows that shared decision making is effective in improving the quality of end of life care, and that it rarely happens; new interventions are needed. Four Conversations is an evidence-based, online curriculum that facilitates shared decision making. This presentation will report the impact of Four Conversations on key outcomes. Methods: Individuals with metastatic breast cancer and caregivers are being recruited nationally. Consenting participants are randomized 1:1 to the treatment or wait-listed control arm. Treatment arm participants access content online; required activities included viewing interactive videos and completing workbook activities. Surveys are administered at Baseline, Week-4, and Week-8 via REDCap to assess for: decision making self-efficacy and conflict; and program satisfaction. An independent-samples t-test was conducted to compare change in decision making outcomes in treatment and usual care conditions at Week-4. A paired-samples t-test was used to access for changes in outcomes from Baseline to Week-8 among the treatment arm. Results: Participants (n = 138) were: mean age 53.2 (11.8) years; 96% female; 91% white; 72% married. There was significant improvement in decision making self-efficacy and reduction in conflict among the treatment arm at follow-up (p &lt; .05). There was no significant change in decision making self-efficacy and conflict scores for treatment and wait-listed control conditions at the end of the intervention (p &gt; .05). Among treatment arm participants who did not already have an advanced care directive, most (56%) completed one. Most participants (88%) would recommend Four Conversations to others and felt that the program better prepared them to make better decisions. Conclusions: While these results are preliminary (i.e., data collection continues through 9/2017), they suggest that Four Conversations may effect decision-making outcomes for metastatic breast cancer patients and caregivers. Additional research is recommended with larger and more diverse samples following completion of this study. Clinical trial information: NCT02944344.
Utilizing advance care planning videos to empower perioperative cancer patients and families: Results from a randomized controlled trial.
Authors: Rebecca Aslakson, Sarina Isenberg, Norah L. Crossnohere, Alison M. Conca-Cheng, Madeleine Moore, Akshay Bhamidipati, Silvia Mora, Judith Miller, Sarabdeep Singh, Susan Larson, Sandy Swoboda, Timothy M. Pawlik, Matthew J. Weiss, Angelo E. Volandes, Thomas J. Smith, John F.P. Bridges, Debra Roter
Journal: Journal of Clinical Oncology (2017)

5 Background: The feasibility and impact of integrating advance care planning (ACP) in surgical oncologic populations is unknown. We hypothesized that an ACP video could be integrated into surgical oncologic care and that patients who preoperatively viewed the video would engage in more ACP and patient-centered communication with their surgeon. Methods: Randomized controlled, phase II trial with two study arms: intervention ACP video and control (no ACP) video; and four data collection periods: enrollment, presurgical consent, postoperative one week, and postoperative one month. Participants included patients undergoing major cancer surgery recruited from nine surgical oncology clinics at a single, academic, inner city, tertiary care hospital. Main Outcomes and Measures: Primary Outcome - Content of ACP and patient-centeredness during the presurgical consent visit as measured through the Roter Interaction Analysis System (RIAS). Secondary patient outcomes – mood; goals of care; and video helpfulness. Results: Ninety-two patients (target enrollment of ninety) were enrolled over 15 months. The ACP video was successfully integrated into the intervention arm and no study-related harms were noted. Patient-centeredness was unchanged between the study arms (IRR=1.06, CI [0.87,1.3], p=0.545) and there was a trend of increased ACP content in the intervention arm (23% intervention vs. 10% control, p=0.182). There were no differences in secondary outcomes other than patients found the intervention video more “helpful” (p=0.007). There was a statistically significant increase in mood symptoms in both groups one week post-operative as compared to enrollment (p=0.01). Patients in both groups most frequently noted cure-related goals of care. Conclusions: The ACP video was integrated successfully into surgical care, well-tolerated, and thought helpful by patients, but did not significantly change the nature or ACP content in patient-surgeon pre-operative conversation. Future studies could increase the “dose” of ACP through modifying video content and/or how or who presents that content prior to surgery. Clinical trial information: NCT02489799.
A three step process to create a palliative medicine co-management model of care on an inpatient hematology unit.
Authors: Gene Decastro, Bridget Earle
Journal: Journal of Clinical Oncology (2017)

141 Background: Northwell Health’s North Shore University Hospital (NSUH) campus has a dedicated hematology unit. This cohort of patients is under-represented on our inpatient palliative care service, comprising &lt; 1% of initial consultations in 2016. Given recent recommendations by the American Society of Clinical Oncology about comprehensive cancer care, and recognizing the growing need for palliative care for patients with hematological malignancies, our goal was to initiate a concurrent hematologic and palliative care delivery model. Methods: A three step process was initiated – inpatient service buy-in and joint workgroup development, concurrent care delivery, and linkage to outpatient partners. The first step was to obtain buy-in with faculty stakeholders at our institution, including Hematology-Oncology leadership. There was immediate support for a partnership. Next, a workgroup was assembled to jointly generate a needs assessment survey to determine how best to assist in the care of these complex patients. Additionally, we identified key metrics to measure, and linked our inpatient service with outpatient care via our Supportive Oncology practice. Results: The five month process culminated in biweekly “screening rounds” with the Hematology team which were initiated in June 2017 and used as a first step to identify high-need patients for consultation. The workgroup agreed upon performance metrics which included hematologic diagnosis, reason for consult, time to consult from admission, length of stay, documentation of advance directives and goals of care, and outpatient referrals. Conclusions: Through relationship management, workgroup development, and care transition to community, an inpatient supportive care co-management model for patients with hematologic malignancies was successfully implemented using a three-step process. This format and strategy can be replicated for other services with complex patients. Future analysis of the outcome metrics will be able to provide feedback to the Palliative – Hematology services. By creating health care pathways with an emphasis on Palliative Medicine co-management, we are poised to deliver comprehensive care and measure its impact.
Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis
Authors: Yuri Ciervo, Ke Ning, Xu Jun, Pamela J. Shaw, Richard J. Mead
Journal: Molecular Neurodegeneration (2017)

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative condition where loss of motor neurons within the brain and spinal cord leads to muscle atrophy, weakness, paralysis and ultimately death within 3–5 years from onset of symptoms. The specific molecular mechanisms underlying the disease pathology are not fully understood and neuroprotective treatment options are minimally effective. In recent years, stem cell transplantation as a new therapy for ALS patients has been extensively investigated, becoming an intense and debated field of study. In several preclinical studies using the SOD1G93A mouse model of ALS, stem cells were demonstrated to be neuroprotective, effectively delayed disease onset and extended survival. Despite substantial improvements in stem cell technology and promising results in preclinical studies, several questions still remain unanswered, such as the identification of the most suitable and beneficial cell source, cell dose, route of delivery and therapeutic mechanisms. This review will cover publications in this field and comprehensively discuss advances, challenges and future direction regarding the therapeutic potential of stem cells in ALS, with a focus on mesenchymal stem cells. In summary, given their high proliferation activity, immunomodulation, multi-differentiation potential, and the capacity to secrete neuroprotective factors, adult mesenchymal stem cells represent a promising candidate for clinical translation. However, technical hurdles such as optimal dose, differentiation state, route of administration, and the underlying potential therapeutic mechanisms still need to be assessed.
P2.04-008 ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy
Authors: A. Farago, L. Paz-Ares, A. Fülop, A. Chiappori, K. Syrigos, J. Lopez-Vilariño, C. Kahatt, G. Kos, A. Soto-Matos
Journal: Journal of Thoracic Oncology (2017)
Molluscum Contagiosum in a Patient with Atopic Dermatitis
Authors: Katerina Damevska, Arben Emurlai
Journal: New England Journal of Medicine (2017)

A 7-year-old boy with a history of atopic dermatitis presented to the dermatology clinic with a 3-month history of widespread flesh-colored papules over the chest and axilla. A clinical diagnosis of molluscum contagiosum was made.
Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin
Authors: Xu Wang, Jonathan J. Beitler, Wen Huang, Guo Chen, Guoqing Qian, Kelly Magliocca, Mihir R. Patel, Amy Y. Chen, Jun Zhang, Sreenivas Nannapaneni, Sungjin Kim, Zhengjia Chen, Xingming Deng, Nabil F. Saba, Zhuo Georgia Chen, Jack L. Arbiser, Dong M. Shin
Journal: Clinical Cancer Research (2017)

Purpose: Previous studies revealed diverging results regarding the role of survivin in squamous cell carcinoma of the head and neck (SCCHN). This study aimed to evaluate the clinical significance of survivin expression in SCCHN; the function of survivin in DNA-damage repair following ionizing radiation therapy (RT) in SCCHN cells; and the potential of honokiol to enhance RT through downregulation of survivin.Experimental Design: Expression of survivin in SCCHN patient primary tumor tissues (n = 100) was analyzed and correlated with clinical parameters. SCCHN cell lines were used to evaluate the function of survivin and the effects of honokiol on survivin expression in vitro and in vivoResults: Overexpression of survivin was significantly associated with lymph nodes' metastatic status (P = 0.025), worse overall survival (OS), and disease-free survival (DFS) in patients receiving RT (n = 65, OS: P = 0.024, DFS: P = 0.006) and in all patients with SCCHN (n = 100, OS: P = 0.002, DFS: P = 0.003). In SCCHN cells, depletion of survivin led to increased DNA damage and cell death following RT, whereas overexpression of survivin increased clonogenic survival. RT induced nuclear accumulation of survivin and its molecular interaction with γ-H2AX and DNA-PKCs. Survivin specifically bound to DNA DSB sites induced by I-SceI endonuclease. Honokiol (which downregulates survivin expression) in combination with RT significantly augmented cytotoxicity in SCCHN cells with acquired radioresistance and inhibited growth in SCCHN xenograft tumors.Conclusions: Survivin is a negative prognostic factor and is involved in DNA-damage repair induced by RT. Targeting survivin using honokiol in combination with RT may provide novel therapeutic opportunities. Clin Cancer Res; 24(4); 858-69. ©2017 AACR.
Early integration of supportive oncology consultation for hospitalized cancer patients.
Authors: Kellie Woodfield, Kerin B. Adelson, Jay Horton, Cardinale B. Smith
Journal: Journal of Clinical Oncology (2017)

136 Background: Integration of Palliative Care (PC) for patients with cancer is associated with improved symptom control, clearer understanding of prognosis, lower utilization of health care resources, and increased hospice use. Yet few studies identify which elements of a PC consultation are most associated with improved outcomes, particularly in the inpatient setting. This study describes the processes of a specialized, interdisciplinary, inpatient PC consultation service that utilized standardized referral criteria and demonstrated improved 30-day readmission, oncology service mortality, and hospice utilization. Methods: We implemented a 3-month intervention on the solid tumor oncology service requiring an automatic PC consultation for patients with one or more of the following criteria: stage IV disease, Stage III lung or pancreatic cancer, hospitalization within 30 days, &gt; 7 day hospitalization, or uncontrolled symptoms. Descriptive statistics were used to identify specific processes associated with the consultation. Results: A total of 52 patients were evaluated. The median time of initial consult was on hospital day 2 and patients were followed for an average of 9 days (±11). The majority of patient encounters were by a physician (47%) or advanced practice nurse (42%), with 48% of encounters lasting 35-60 minutes. Integrative services (massage, yoga etc.) were offered in 72% of consults. The most common issues addressed throughout the consultation were pain (85%), non-pain symptoms (85%), transition planning (85%), and plan of care (82%). Overall, consulting teams addressed more PC needs than were initially identified by chart review. Conclusions: Implementing standardized PC consultations in patients with solid malignancies requires the full support of an interdisciplinary team. PC consultations are time-consuming undertakings, often addressing needs broader in scope than initially identified and requiring the use of specialty level PC in the majority of cases. Future efforts to implement similar interventions can use these data to identify specific staffing needs and to ensure cancer patients receive quality care.
Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).
Authors: Michael C. Heinrich, Robin Lewis Jones, Margaret von Mehren, Patrick Schoffski, Sebastian Bauer, Olivier Mir, Philippe Alexandre Cassier, Ferry Eskens, Hongliang Shi, Terri Alvarez-Diez, Oleg Schmidt-Kittler, Mary Ellen Healy, Beni B. Wolf, Suzanne George
Journal: Journal of Clinical Oncology (2017)

11011 Background: Oncogenic mutations in KIT or PDGFRα drive &gt; 85% of GIST. However, primary and acquired mutations in the activation loop of PDGFRα and KIT are not effectively treated by approved therapies. A phase 1 study (NCT02508532) was initiated in advanced GIST to assess the safety, PK and clinical activity of BLU-285, a potent, highly-selective oral inhibitor that targets KIT Exon 17 and PDGFRα D842 activation loop mutants. Methods: Adult patients (pts) with unresectable GIST, who had received ≥2 kinase inhibitors including imatinib or who had a primary PDGFRα D842 mutation regardless of prior therapy, were given BLU-285 once daily on a 4-week cycle following a 3+3 escalation design, which allowed additional accrual to dose levels demonstrated to be safe. Adverse events (AEs) per CTCAE v4.03, PK and plasma/tumor mutant DNA levels were assessed. Response was determined by RECIST 1.1 every 8 weeks. Results: At a 01JAN17 cutoff, 40 pts (21 PDGFRa/19 KIT) have been treated with BLU-285 at doses of 30-600 mg. Median number of prior kinase inhibitor regimens was 4.5 (2-12) KIT/2.5 (0-4) PDGFRα. RECIST 1.1 responses were seen across all dose levels for PDGFRα GIST and at higher dose levels for KIT GIST. Of 17 PDGFRα D842V pts with ≥1 radiographic assessment, 7 had confirmed PR (ORR 41%) and 10 had SD. Of 11 evaluable KIT pts treated at doses ≥ 135 mg, 2 had PR (1 confirmed; ORR 18%) and 5 SD. BLU-285 is rapidly absorbed (T max 2-8 h), exposure increases linearly with dose, and half-life is &gt; 24 h supporting QD dosing. Most AEs were grade 1 or 2, most commonly nausea (48%), fatigue (45%), peripheral edema, periorbital edema, vomiting (30% each), diarrhea (25%), anemia, dizziness, and lacrimation (23% each). There were no grade 4 or 5 BLU-285-related AEs, dose limiting toxicities, or discontinuations. 29 pts (all 21 PDGFRα pts) remain on treatment (duration 1-14 mo). Updated results including MTD, ct-DNA and central radiographic assessments will be presented. Conclusions: Precision targeted therapy with BLU-285 demonstrates important clinical activity in pts with both PDGFRα- and KIT-mutant GIST that is resistant to available therapies. Clinical trial information: NCT02508532.
Abstract 221: Sam68 Interacts With mTORC1 and Contributes to Myocardial Hypertrophy
Authors: Junlan Zhou, Chan Boriboun, Gangjian Qin
Journal: Circulation Research (2016)

Introduction: The Src-associated in mitosis 68 kDa (Sam68) belongs to the STAR (signal transducer and activator of RNA) family of RNA-binding proteins. Our recent work revealed its critical role in the regulation of adipose thermogenesis. However, whether Sam68 regulates cardiomyocyte biology and heart disease is currently unknown. Methods and Results: Echocardiography analyses were performed in Sam68 -/- mice and WT littermates; the baseline left-ventricular wall thickness (LVPWs and LVPWd), chamber size (LVDs and LVDd), and contractility (LVEF and FS) are similar between the 2 groups of animals. However, after transverse aortic constriction (TAC) for 2 and 4 weeks, Sam68 -/- mice exhibited a significantly lesser increase in LV wall thickness (at 2 and 4 weeks), a closer to normal LV chamber size (at 4 weeks), and a lower heart-weight (HW)/body-weight (BW) ratio (at 4 weeks), as compared to WT controls. Consistently, after continuous administration of angiotensin II (by subcutaneous osmotic minipumps) for 2 weeks, Sam68 -/- mice displayed a similarly ameliorated LV wall thickness, chamber size, and HW/BW ratio. The attenuated hypertrophic responses of Sam68 -/- mice to both TAC and Ang II treatment was supported by a lowered expression of fetal genes (β-myosin heavy chain, atrial and brain natriuretic peptides) in the heart (qRT-PCR) and excitingly, by the decreased activity of mTORC1, as indicated by the lowered levels of phosphorylated S6K1 and 4E-BP1 (Western blotting). The cardiomyocyte-specific role of Sam68 was further confirmed in cultured H9c2 cells with lentivirus-mediated Sam68 knockdown, which confirmed the reduction of mTORC1 activity. Furthermore, co- immunoprecipitation assays revealed that the endogenous Sam68 protein interacts Raptor and mTOR, but not Rictor, in the mTOR complex. Experiments are underway to establish the functional significance of the Sam68-mTOR pathway in cardiac hypertrophy and failure in vivo. Conclusion: Collectively, our data suggest that Sam68 is a novel cofactor of mTORC1. It interacts with Raptor to augment mTOR signaling and contribute to the development of cardiac hypertrophy.
Abstract 296: Views on Cardiopulmonary Resuscitation Among Older Australians in Care
Authors: Lahn Straney, Janet Bray, Rachel Mountjoy, Judith Finn
Journal: Circulation (2014)

Background: Our objective was to measure the views of older Australians on Cardiopulmonary Resuscitation (CPR). Methods and Results: A brief explanation of CPR and a three question survey were sent to 187 Australian residential care facilities and 34 home care providers in April 2014. A total of 2213 respondents completed the survey, including 1943 residents from 163 residential care facilities, and 275 receiving care in the home from 24 providers (71% and 49% response rate, respectively). Respondents were mostly female (67.4%), and those in residential care were more likely to be aged over 75 years than those receiving care in the home (82.6% versus 70.4%). The majority of respondents indicated they understood what CPR is and what it means for them (Table). Over half indicated they would want CPR if required (55.1% for residents and 65.3% for those receiving home care), this was higher among younger residents (64.2% in ≤ 75 years and 53.2% in&gt;75 years) but similar by sex. A large proportion believed they would fully recover after receiving CPR (44.1% of residential care and 58.1% of home care residents). Of those who agreed there was a good chance they would fully recover, almost all stated they would like to receive CPR if they had an arrest (94.8% of residential care and 91.4% of home care residents). Conversely, of those that disagreed, 98.6% of residential and 96.2% of home care respondents were unsure about or disagreed to receiving CPR. Conclusions: The desire for CPR in this population appears to be related to their perception as to whether or not they will fully recover. Outcomes for older people who have an arrest are typically poor. Despite this, a large proportion of respondents believed they would recover to their previous health state if they were to receive CPR. These findings highlight the need for more accurate information to inform discussions about end-of-life decisions.
14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in T C 2 and CD8 + lymphocytes from patients with scleroderma
Authors: Sandra Cascio, Thomas A. Medsger, William F. Hawse, Simon C. Watkins, Christine Milcarek, Larry W. Moreland, Robert A. Lafyatis, Patrizia Fuschiotti
Journal: Journal of Allergy and Clinical Immunology (2017)